HDCN Abstract:  ASN Annual Meeting 2020 -- Digital Meeting  

Barratt J, Tumlin JA, Suzuki Y, et al.

24-Week Interim Analysis of a Randomized, Double-Blind, PlaceboControlled Phase 2 Study of Atacicept in Patients with IgA Nephropathy and Persistent Proteinuria

ASN Annual Meeting 2020 -- Digital Meeting
J Am Soc Nephrol (Oct) 31:54A 2020

BACKGROUND

IgA nephropathy (IgAN) is the most common primary glomerulonephritis and currently has no approved therapy. Its central pathogenic feature is circulating immune complexes of poorly O-galactosylated polymeric IgA1 (Gd-IgA1) that often deposit in the kidneys (causing inflammation and scarring) and trigger formation of IgA/G autoantibodies. Atacicept, a human TACI-Ig fusion protein, inhibits B cell-stimulating factors BLyS and APRIL and is associated with reduced serum IgA/G, mature B cells and plasma cells. This Phase II study (NCT02808429) examines atacicept safety and efficacy in reducing Gd-IgA1 and renal activity in IgAN.

METHODS

Patients with IgAN and proteinuria ≥1 g/day or 0.75 mg/mg on 24-hr urine protein-creatinine ratio (UPCR) despite maximal standard of care (ACE inhibitor and/or ARB) were enrolled. Patients were randomized to subcutaneous placebo, atacicept 25mg or 75mg weekly. Primary endpoint: change in proteinuria at Week 48; secondary endpoints: changes in eGFR, serum IgA, IgG, and IgM, and Gd-IgA1.

RESULTS

This interim analysis showed that, at Week 24, IgAN patients (placebo=5; atacicept 25mg=6; 75mg=5) had a consistent, dose-dependent reduction in IgA, IgG and IgM, and in Gd-IgA1 (Fig 1A), and a higher median % reduction from baseline in UPCR with atacicept than with placebo (Fig 1B); eGFR remained stable. TEAEs were reported by 81% of patients (mild/moderate, none severe), with no serious related events, severe hypogammaglobulinemia, or fatal outcomes.

CONCLUSION

These results provide proof of concept for the potential treatment of patients with IgAN and persistent proteinuria with atacicept.


Figure 1. Median changes from baseline to Week 24 in a) serum Gd-IgA1 and b) 24-hour UPCR

c Copyright 2020 -2021 American Society of Nephrology. Reproduced with permission.
All ASN abstracts from the 2020 Annual Meeting are available at this link and also are archived in .pdf form at ASN-Online.org

Disclaimer: Abstracts often have errors, both typographical and otherwise. This posting is an electronic translation of submitted abstracts which has not been verified against the original submitted abstract nor with the authors for accuracy. As a result, there may be errors, especially with regard to drug doses, but not limited to these. Abstracts undergo only limited review, and data often are changed as a result of the peer review process, so their reliability is less than manuscripts published in peer-reviewed journals. In using these summaries, you are agreeing that you are aware of these limitations.

The materials are provided on an as-is basis without any warranty of any kind, either express or implied. In addition to errors, the information presented may be incomplete or outdated. The information contained is not intended nor recommended as a substitute for professional medical advice. You are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each device to be used or drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug, disease, and the best treatment for the patient.

To the fullest extent permitted by law, HDCN, ASN and their affiliates and suppliers disclaim all warranties, express or implied, including, but not limited to, any warranty of merchantability, non- infringement or fitness for a particular purpose.

In no event shall HDCN, ASN, or their affiliates or suppliers be liable for any damages whatsoever (including, but not limited to, direct, indirect, incidental, consequential, punitive or exemplary damages, or any damages for loss of profits, use, data, goodwill or other intangibles) arising from or in any way relating to these terms, the materials, or any information, goods or services obtained from or referred to in the materials, whether based on warranty, contract, tort (including, but not limited to, negligence), or any other legal theory, and whether or not any or all of the limited entities is advised of the possibility of such damages.